Author: Editor

Rosario Campelo, MD of University Hospital of A Coruña discusses ALUNBRIG (brigatinib) as a first-line treatment for ALK + non-small cell lung cancer. ______________ ALUNBRIG’s Phase 3 ALTA-1L (ALK in BrigAtinib’s Lung Cancer Trial in 1st line) study in adults is a global, ongoing, randomized, open-label, comparative, multicenter study that enrolled 275 patients (ALUNBRIG, n=137, crizotinib, n=138) with ALK+ locally advanced or metastatic NSCLC who did not receive an ALK inhibitor prior care. Patients received either ALUNBRIG, 180 mg once daily at 90 mg once daily with seven-day lead-in, or crizotinib, 250 mg twice daily. In the ALUNBRIG arm the…

Prakash Bhuyan, M.D., Ph.D. of INOVIO Pharmaceuticals @InovioPharma discusses the Phase 2 VGX-3100 results In patients with HPV-associated Anal Dysplasia. _____________ INOVIO Pharmaceuticals, Inc. (NASDAQ: INO) today reported promising interim results from an open-label, Phase 2 study showing its lead DNA candidate VGX-3100 to be safe and successful in treating men and women with anal dysplasia, also known as high-grade squamous intraepithelial lesion (HSIL), a precancerous disease caused by high-risk human papillomavirus (HPV) forms 16/18. Of the 20 subjects that had findings at the time of data analysis, 50 percent (10 out of 20 subjects) showed clearance of precancerous lesions…

Prakash Bhuyan, M.D., Ph.D. of INOVIO Pharmaceuticals @InovioPharma discusses the Phase 2 VGX-3100 results In patients with HPV-associated Anal Dysplasia. _____________ INOVIO Pharmaceuticals, Inc. (NASDAQ: INO) today reported promising interim results from an open-label, Phase 2 study showing its lead DNA candidate VGX-3100 to be safe and successful in treating men and women with anal dysplasia, also known as high-grade squamous intraepithelial lesion (HSIL), a precancerous disease caused by high-risk human papillomavirus (HPV) forms 16/18. Of the 20 subjects that had findings at the time of data analysis, 50 percent (10 out of 20 subjects) showed clearance of precancerous lesions…

Prakash Bhuyan, M.D., Ph.D. of INOVIO Pharmaceuticals @InovioPharma discusses the Phase 2 VGX-3100 results In patients with HPV-associated Anal Dysplasia. _____________ INOVIO Pharmaceuticals, Inc. (NASDAQ: INO) today reported promising interim results from an open-label, Phase 2 study showing its lead DNA candidate VGX-3100 to be safe and successful in treating men and women with anal dysplasia, also known as high-grade squamous intraepithelial lesion (HSIL), a precancerous disease caused by high-risk human papillomavirus (HPV) forms 16/18. Of the 20 subjects that had findings at the time of data analysis, 50 percent (10 out of 20 subjects) showed clearance of precancerous lesions…

John Seymour, PhD of @PeterMacCC discusses year analysis of murano study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed refractory (R/R) chronic lymphocytic leukemia (CLL): how this affects clinicians and what is to come.   venetoclax-rituximab, VenR, chronic lymphocytic leukemia, CLL, murano study

Philadelphia, PA (April 7, 2020) – Oncoceutics, Inc., a clinical-stage drug discovery and development company with a novel class of compounds called imipridones, announced today that Wolfgang Oster, MD, PhD, one the company’s co-founders and Chief Executive Officer, has left the company effective April 3 as part of a leadership change.  He has also left the company’s Board of Directors. Raymond Wong, a director associated with the company’s lead investor, Spring Mountain Capital, is now the company’s Chairman. Lee Schalop, MD, the company’s Chief Operating Officer, is now Chief Executive Officer. Martin Stogniew, PhD, remains the company’s Chief Development Officer. Josh…

Dr. Sumit Subudhi, M.D., Ph.D. of @MDAndersonNews explains the phase II trial in effective immunotherapy with markers of immune activation in metastatic prostate cancer.  While metastatic castration-resistant prostate cancer (mCRPC) usually has minimal response to immunotherapy, in a Phase II trial at The University of Texas MD Anderson Cancer Center, a subset of patients with pretreatment evidence of active T-cell responses in their tumors observed sustained survival following treatment with ipilimumab. “Our results indicate that immune checkpoint blockade can instigate T-cell responses to tumor neoantigens despite a low tumor mutational burden in prostate cancer,” said lead author Sumit Subudhi, M.D., Ph.D.,…

Dr. Sumit Subudhi, M.D., Ph.D. of @MDAndersonNews answers if the markers are predictive of outcomes on immunotherapy with markers of immune activation in metastatic prostate cancer. While metastatic castration-resistant prostate cancer (mCRPC) usually has minimal response to immunotherapy, in a Phase II trial at The University of Texas MD Anderson Cancer Center, a subset of patients with pretreatment evidence of active T-cell responses in their tumors observed sustained survival following treatment with ipilimumab. “Our results indicate that immune checkpoint blockade can instigate T-cell responses to tumor neoantigens despite a low tumor mutational burden in prostate cancer,” said lead author Sumit Subudhi,…

Dr. Sumit Subudhi, M.D., Ph.D. of @MDAndersonNews discusses effective immunotherapy with markers of immune activation in metastatic prostate cancer. While metastatic castration-resistant prostate cancer (mCRPC) usually has minimal response to immunotherapy, in a Phase II trial at The University of Texas MD Anderson Cancer Center, a subset of patients with pretreatment evidence of active T-cell responses in their tumors observed sustained survival following treatment with ipilimumab. “Our results indicate that immune checkpoint blockade can instigate T-cell responses to tumor neoantigens despite a low tumor mutational burden in prostate cancer,” said lead author Sumit Subudhi, M.D., Ph.D., assistant professor of Genitourinary Medical Oncology.…

David Spetzler, MS of Caris Life Sciences @carisls discusses the MI FOLFAXai: how information is generated. A leading molecular science innovator focused on delivering on the promise of precision medicine, today announced the launch of MI FOLFOXaiTM, the latest addition to the company’s extensive molecular science portfolio. MI FOLFOXai is an Artificial Intelligence (AI)-based predictor of FOLFOX chemotherapy response in metastatic colorectal cancer that showed an increase of approximately 50 percent in overall survival through two independent validation studies. Using the findings of Caris Molecular Intelligence ® tumor profiling, this AI-powered predictor is designed to gage the probability of a…

David Spetzler, MS of Caris Life Sciences @carisls discusses the MI FOLFAXai. A leading molecular science innovator focused on delivering on the promise of precision medicine, today announced the launch of MI FOLFOXaiTM, the latest addition to the company’s extensive molecular science portfolio. MI FOLFOXai is an Artificial Intelligence (AI)-based predictor of FOLFOX chemotherapy response in metastatic colorectal cancer that showed an increase of approximately 50 percent in overall survival through two independent validation studies. Using the findings of Caris Molecular Intelligence ® tumor profiling, this AI-powered predictor is designed to gage the probability of a patient benefiting from FOLFOX…

A leading molecular science innovator focused on delivering on the promise of precision medicine, today announced the launch of MI FOLFOXaiTM, the latest addition to the company’s extensive molecular science portfolio. MI FOLFOXai is an Artificial Intelligence (AI)-based predictor of FOLFOX chemotherapy response in metastatic colorectal cancer that showed an increase of approximately 50 percent in overall survival through two independent validation studies. Using the findings of Caris Molecular Intelligence ® tumor profiling, this AI-powered predictor is designed to gage the probability of a patient benefiting from FOLFOX in combination with bevacizumab as a first-line regimen. Two separate data sets…

Dr. Giuseppe Curigliano, MD, PhD @curijoey of University of Milan on patient care and COVID-19 containment in Italy. Read here: https://dailynews.ascopubs.org/do/10.1200/ADN.20.200068/full/?cid=DM4782&bid=40579286

Wenyin Shi, MD of Jefferson Health @TJUHospital #JeffersonHealth discusses the patients with newly diagnosed glioblastoma, initial experience with scalp saving radiation using combined temozolomide and tumor treatment fields (SPARE). Glioblastoma care quality involves concomitant chemoradiation and temozolomide management with tumor treatment fields (TTF fields). Preclinical studies indicate synergistic effects of TTF fields, and radiation therapy. We record our initial experience evaluating scalp-sparing radiation toxicity and tolerability with concurrent TTFields. This is a pilot test with one arm (Clinicaltrials.gov Identifier: NCT03477110). Adult patients (age from 18 years) with KPS from 60 years of age were eligible for newly diagnosed glioblastoma. All…

Dr. Adil Akhtar, MD of Karmanos Cancer Institute discusses important points to note on the rapidly changing COVID-19 for cancer patients and treatment. Early reports concerning cancer patients from Wuhan, China — the initial COVID-19 pandemic epicenter — indicate that many have contracted the coronavirus while in hospital care. That may mean that this vulnerable group may need to consider delaying treatment for cancer to help reduce their chances of infection.  Read here: https://www.webmd.com/lung/news/20200325/covid-19-may-delay-some-cancer-treatments#1

Dr. Adil Akhtar, MD of Karmanos Cancer Institute discusses COVID-19 possibly delaying cancer treatments because during treatment, patients may be exposed to the coronavirus. Early reports concerning cancer patients from Wuhan, China — the initial COVID-19 pandemic epicenter — indicate that many have contracted the coronavirus while in hospital care. That may mean that this vulnerable group may need to consider delaying treatment for cancer to help reduce their chances of infection.  Read here: https://www.webmd.com/lung/news/20200325/covid-19-may-delay-some-cancer-treatments#1

Wenyin Shi, MD of Jefferson Health @TJUHospital #JeffersonHealth answers common questions asked on the patients with newly diagnosed glioblastoma, initial experience with scalp saving radiation using combined temozolomide and tumor treatment fields (SPARE).  Glioblastoma care quality involves concomitant chemoradiation and temozolomide management with tumor treatment fields (TTF fields). Preclinical studies indicate synergistic effects of TTF fields, and radiation therapy. We record our initial experience evaluating scalp-sparing radiation toxicity and tolerability with concurrent TTFields. This is a pilot test with one arm (Clinicaltrials.gov Identifier: NCT03477110). Adult patients (age from 18 years) with KPS from 60 years of age were eligible for…

What is KEYNOTE-189? Shirish Gadgeel, MBBS of U-M Rogel Cancer Center @UMRogelCancer discusses important points to note in NSCLC. In KEYNOTE-189, first- pembrolizumab plus pemetrexed- significantly improved overall survival (OS) and progression- survival (PFS) compared to placebo plus pemetrexed- in patients with non– non- metastatic lung cancer (NSCLC), regardless of the expression of tumor programmed death- 1 (PD-). Patients were allocated randomly (2:1) to receive pemetrexed and platinum plus pembrolizumab (n=410) or placebo (n=206) for 4 cycles every 3 weeks, then pemetrexed maintenance plus pembrolizumab or placebo for up to 35 cycles in total. In the placebo-combination category, eligible patients…

Shirish Gadgeel, MBBS of U-M Rogel Cancer Center @UMRogelCancer answers common questions on KEYNOTE-189. If the PD-L1 expression is less than 1%, should therapy for pembrolizumab be considered in NSCLC? In KEYNOTE-189, first- pembrolizumab plus pemetrexed- significantly improved overall survival (OS) and progression- survival (PFS) compared to placebo plus pemetrexed- in patients with non– non- metastatic lung cancer (NSCLC), regardless of the expression of tumor programmed death- 1 (PD-). Patients were allocated randomly (2:1) to receive pemetrexed and platinum plus pembrolizumab (n=410) or placebo (n=206) for 4 cycles every 3 weeks, then pemetrexed maintenance plus pembrolizumab or placebo for up…

Philadelphia, PA (April 1, 2020) – Oncoceutics, Inc., announced that it was informed by its Japanese licensee, Ohara Pharmaceutical Co., Ltd., of the initiation of a Phase I/II clinical study of OP-10 (the Japanese name for ONC201) in Japan and the administration of the drug to the first patient.  ONC201 is a novel small molecule with a unique mechanism of action that has demonstrated anti-cancer activity and safety in preclinical models and in several ongoing clinical trials, including clinical trials in adult and pediatric patients with high-grade glioma. In February 2019, Oncoceutics outlicensed rights to ONC201 for Japan to Ohara. Under…

Philadelphia, PA (March 26, 2020) – Oncoceutics, Inc. announced that the Chinese National Intellectual Property Administration (CNIPA) has issued a Notice of Allowance for a Composition of Matter patent for ONC201, the company’s lead development candidate, as well as for several other compounds of the imipridone family.  This new patent, along with a Composition of Matter patent for ONC201 issued in the United States in March 2019 and an intention to grant from the European Patent Office issued in August 2019, gives Oncoceutics extensive coverage for ONC201 around the world.  Oncoceutics licensed this group of patents from The Scripps Research Institute…

Shirish Gadgeel, MBBS of U-M Rogel Cancer Center @UMRogelCancer discusses an updated analysis on KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for untreated metastatic NSCLC. In KEYNOTE-189, first- pembrolizumab plus pemetrexed- significantly improved overall survival (OS) and progression- survival (PFS) compared to placebo plus pemetrexed- in patients with non– non- metastatic lung cancer (NSCLC), regardless of the expression of tumor programmed death- 1 (PD-). Patients were allocated randomly (2:1) to receive pemetrexed and platinum plus pembrolizumab (n=410) or placebo (n=206) for 4 cycles every 3 weeks, then pemetrexed maintenance plus pembrolizumab or placebo for up to 35 cycles in…

Amy Moore, PhD @amoorephd of GO2 Foundation of Lung Cancer @GO2Foundation explains that COVID-19 infection rate is doubled for cancer patients. The coronavirus disease, called COVID-19, is in the minds of many people at the front and centre. For so many this is troubling, particularly for cancer patients and their families. Now declared by the World Health Organization (WHO) as a pandemic, the majority of people who develop COVID-19 experience only mild symptoms, including colds. WHO says that 80 percent of COVID-19 people are recovering without needing any specialist care. According to the CDC, some groups, including elderly adults and…

Heinz-Josef Lenz, MD Professor of Medicine and Preventive Medicine Associate Director, Clinical Sciences J Terrence Lanni Chair in Cancer Research Director, USC Center for Molecular Pathways and Drug Discovery USC / Norris Comprehensive Cancer Center outlines an Update on Molecular Targeted Therapies for Metastatic colorectal cancers including in depth conversation on Next-generation sequencing, The Colorectal Cancer Subtyping Consortium, bevacizumab, EGFR, 80405 trial, Gerlinger et al., NEJM 2012, Circos plot illustrating genome-wide CNA, Liquid Biopsies, KRAS, MGH GI, RAS-WT CRC, ctDNA, CALGB, SWOG 80405, Cetuximab, FOLFIRI, FOLFOXIRI, CRICKET Trial, PD-1 Blockade, Nivolumab Monotherapy, BRAF, HER2 Overexpression,Trastuzumab,HER2, ZW25, DS-8201a, BEACON CRC Phase…

Amy Moore, PhD @amoorephd of GO2 Foundation of Lung Cancer @GO2Foundation discusses the intersection of COVID-19 and lung cancer patients. The coronavirus disease, called COVID-19, is in the minds of many people at the front and centre. For so many this is troubling, particularly for cancer patients and their families. Now declared by the World Health Organization (WHO) as a pandemic, the majority of people who develop COVID-19 experience only mild symptoms, including colds. WHO says that 80 percent of COVID-19 people are recovering without needing any specialist care. According to the CDC, some groups, including elderly adults and people…

Tanya Dorff, MD Associate Clinical Professor of MedicineHead of Genitourinary Cancer Program City of Hope discusses Genitourinary Cancers:Evolving Practices and Controversies, STAMPEDE: (Docetaxel) in mHSPC, LATITUDE Trial, docetaxel, ENZAMET, SWOG S1802, TITAN, mCRPC, Cabazitaxel, Enzalutamide, Radium223, Sipuleucel-T, Docetaxel (TAX), ADT, A031201, EORTC 1333 / PEACE III2, PARP inhibitors, TOPARP- B, niraparib, rucaparib, talazoparib, PHASE III PROFOUND, Pembrolizumab, KEYNOTE-991, 177-Lu PSMA, VISION trial, CAR-T, BiTE antibody, Erdafitinib, FGFR TKI, Enfortumab, EV 302, Docetaxel, Vofatamab, nivoluamb and more at the MOASC Summit 2020 Sponsors: AbbVie  AMAG AstraZeneca  Bayer  BeiGene  Clovis Oncology Coherus  Daiichi-Sankyo  Dova Pharmaceuticals  Foundation Medicine  Jazz Pharmaceuticals   Merck  Pfizer Oncology …

Zev A. Wainberg, MD Associate Professor Of Medicine Co-Director GI Oncology Program David Geffen School of Medicine at UCLA gives an update in Gastrointestinal Cancers including KEYNOTE-059, Pembrolizumab, MSI-H KN 059, MSI-H KN 059 061, KEYNOTE 181, KEYNOTE-062, KEYNOTE 59, KEYNOTE-811, CHECKMATE-649, Javelin Gastric 100, SPOTLIGHT (FAST-2) 1L Claudin+, FIGHT 1L FGFR2, PRODIGE 24/CCTG PA.6 trial at the MOASC Summit 2020 Sponsors: AbbVie  AMAG AstraZeneca  Bayer  BeiGene  Clovis Oncology Coherus  Daiichi-Sankyo  Dova Pharmaceuticals  Foundation Medicine  Jazz Pharmaceuticals   Merck  Pfizer Oncology  Puma Biotechnology  Tempus  Verastem oncology Walgreens 

Nick McAndrew, MD MSCE Clinical Instructor Division of Hematology / Oncology UCLA David Geffen School of Medicine discusses updates in Breast CancerSummary of 2019 practice changing studies Overall Survival UpdatesCDK 4/6 Inhibitors: MONALEESA 3, 7 and MONARCH 2, Adjuvant Pertuzumab: APHINITY, ER+, First PI3K Inhibitor Approval: SOLAR-1, HER2+, Tyrosine Kinase Inhibitors: NALA, HER2CLIMB, New ADC: DESTINY-Breast01Triple Negative, Checkpoint Inhibitor in mBC: IMpassion130 Neoadjuvant Checkpoint Inhibitors: KEYNOTE-522, NeoTRIP at the MOASC Summit 2020 Sponsors: AbbVie  AMAG AstraZeneca  Bayer  BeiGene  Clovis Oncology Coherus  Daiichi-Sankyo  Dova Pharmaceuticals  Foundation Medicine  Jazz Pharmaceuticals   Merck  Pfizer Oncology  Puma Biotechnology  Tempus  Verastem oncology Walgreens 

Herbert Eradat, MD, MS @dgsomucla Associate Clinical Professor UCLE Lymphoma Program UCLA BMT & CAR-T Cell Program, David Geffen School of Medicine UCLA discusses An Update on Diffuse Large B-Cell Lymphoma Novel Therapeutic Strategies at the MOASC Summit 2020 Sponsors: AbbVie  AMAG AstraZeneca  Bayer  BeiGene  Clovis Oncology Coherus  Daiichi-Sankyo  Dova Pharmaceuticals  Foundation Medicine  Jazz Pharmaceuticals   Merck  Pfizer Oncology  Puma Biotechnology  Tempus  Verastem oncology Walgreens 

Nagi El Saghir, MD @NagiSaghir of American University of Beirut Medical Center @AUBMC_Official discusses how to care for oncology patients and being educated during the current COVID-19 pandemic. As with the majority of the world’s population, hematologists, oncologists and their patients are now on the alert to face the COVID-19 pandemic worldwide. Indeed we are among the most worried as our patients might be more vulnerable. Owing to regular routine visits to clinics and hospitals, our patients are at higher risk of contracting the virus and, if they acquire COVID-19, they are at higher risk of severe complications and mortality…

Tamer Othman, MD @tamerothman10 of Harbor-UCLA Medical Center @HarborUCLA answers common questions on the characteristics and trends in adult acute lymphoblastic leukemia. There is still a survival benefit for patients who are referred, even if they do not undergo transplant, because of therapy and clinical trials. ______________ It is difficult to treat acute lymphoblastic leukemia (ALL) in a socioeconomic distressed community without ready access to a center for hematopoietic stem cell transplantation (HCT), and clinical trials. Sparse data concerning the outcomes of these patients. This retrospective study included 90 consecutive ALL patients, who presented between 2003 and 2018 to Harbor-UCLA.…

Tamer Othman, MD @tamerothman10 of Harbor-UCLA Medical Center @HarborUCLA discusses the characteristics and trends in adult acute lymphoblastic leukemia. The primary objective was overall survival. Secondary objectives included leukemia-free survival, toxicities of therapy, and referral for HCT and incidence of successful HCT. ALL in a vulnerable population without access to an HCT center is challenging. ______________ It is difficult to treat acute lymphoblastic leukemia (ALL) in a socioeconomic distressed community without ready access to a center for hematopoietic stem cell transplantation (HCT), and clinical trials. Sparse data concerning the outcomes of these patients. This retrospective study included 90 consecutive ALL…

Shebli Atrash, MD @atrashshebli of @atriumhealth @levinecancer explains CAR-T treatment in hematological malignancies affecting clinicians and moving forward with the COVID-19 pandemic. Chemeric antigen receptor (CAR)-T-cell therapy has ignited a surge of hope in hematological malignancies, embodied in the positive outcomes of early clinical trials involving pre-B-cell acute lymphoblastic leukemia, B-cell lymphoma and multiple myeloma patients. CAR-T-cell therapy is considered a groundbreaking treatment for immunotherapy, with the ability to cure many hematological cancers. Nevertheless, new problems have arisen as the use of CAR-T-cell therapy has increased. Such challenges include the manufacturing process of the CAR-T cells, the resistance mechanisms that…

Shebli Atrash, MD @atrashshebli of @atriumhealth @levinecancer answers commong questions on CAR-T treatment in hematological malignancies and the toxicities used. Chemeric antigen receptor (CAR)-T-cell therapy has ignited a surge of hope in hematological malignancies, embodied in the positive outcomes of early clinical trials involving pre-B-cell acute lymphoblastic leukemia, B-cell lymphoma and multiple myeloma patients. CAR-T-cell therapy is considered a groundbreaking treatment for immunotherapy, with the ability to cure many hematological cancers. Nevertheless, new problems have arisen as the use of CAR-T-cell therapy has increased. Such challenges include the manufacturing process of the CAR-T cells, the resistance mechanisms that underlie disease…

Shebli Atrash, MD @atrashshebli of @atriumhealth @levinecancer discusses CAR-T treatment in hematological malignancies.   Chemeric antigen receptor (CAR)-T-cell therapy has ignited a surge of hope in hematological malignancies, embodied in the positive outcomes of early clinical trials involving pre-B-cell acute lymphoblastic leukemia, B-cell lymphoma and multiple myeloma patients. CAR-T-cell therapy is considered a groundbreaking treatment for immunotherapy, with the ability to cure many hematological cancers. Nevertheless, new problems have arisen as the use of CAR-T-cell therapy has increased. Such challenges include the manufacturing process of the CAR-T cells, the resistance mechanisms that underlie disease relapse, adverse effects and cost. This…

This quick tutorial shows in detail how to create an account on OncologyTube.com and how to upload a video. The account is free and you will be able to add oncology and cancer specific videos and share them with our robust health care professional network.

Omid Hamid MD Chief, Translational Research/Immuno-Oncology Director, Experimental Therapeutics Cedars Sinai Foundation discusses the Multi-Modality Management of Melanoma in the Era of Immunotherapy This presentation is a part of the MOASC Oncology Summit Annual Educational Symposium This presentation was made possible by these companies: Abbvie Oncology Amag Pharmaceuticals AstraZeneca Bayer Oncology BeiGene Clovis Oncology Coherus BioSciences Daiichi-Sankyo Jazz Pharmaceuticals Merck Pfizer Oncology Puma Biotechnology Takeda Oncology Tempus Verastem Oncology Walgreens    

Robert Kreitman, MD of @NIHClinicalCntr @NIH discusses the phase II study of cladribine with delayed or concurrent rituximab in patients with hairy cell leukemia: how this affects clinicians and treatment. _________________ Single-agent purine analog, usually cladribine, has been the preferred hairy cell leukemia (HCL) first-line therapy for 30 years. High levels of complete remission (CR) often include minimal residual disease (MRD) which leads to relapse and repeated treatments. Rituximab may clear MRD but uncertain and optimal timing of rituximab is unclear for long-term performance. Patients were randomly administered first-line cladribine 0.15 mg / kg intravenously 1-5 days with 8 weekly…

Robert Kreitman, MD of @NIHClinicalCntr @NIH discusses the phase II study of cladribine with delayed or concurrent rituximab in patients with hairy cell leukemia: what is the significance of this? _________________ Single-agent purine analog, usually cladribine, has been the preferred hairy cell leukemia (HCL) first-line therapy for 30 years. High levels of complete remission (CR) often include minimal residual disease (MRD) which leads to relapse and repeated treatments. Rituximab may clear MRD but uncertain and optimal timing of rituximab is unclear for long-term performance. Patients were randomly administered first-line cladribine 0.15 mg / kg intravenously 1-5 days with 8 weekly…

Robert Kreitman, MD of @NIHClinicalCntr @NIH discusses the phase II study of cladribine with delayed or concurrent rituximab in patients with hairy cell leukemia. _________________ Single-agent purine analog, usually cladribine, has been the preferred hairy cell leukemia (HCL) first-line therapy for 30 years. High levels of complete remission (CR) often include minimal residual disease (MRD) which leads to relapse and repeated treatments. Rituximab may clear MRD but uncertain and optimal timing of rituximab is unclear for long-term performance. Patients were randomly administered first-line cladribine 0.15 mg / kg intravenously 1-5 days with 8 weekly doses of rituximab 375 mg /…

Steven Lin, MD, PhD @StevenLin_MDPhD of @MDAndersonNews addresses how the randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer affects clinicians and treatment today. ____________ It is uncertain if the dosimetric advantages of proton beam therapy (PBT) lead to better health results as opposed to intensity-modulated radiation therapy (IMRT). This randomized trial compared total toxicity burden (TTB) and progression-free survival (PFS) between these esophageal cancer modalities. This phase IIB trial randomly allocated PBT or IMRT patients (50.4 Gy), stratified for histology, resectability, chemotherapy for induction, and level. TTB and PFS were the…

Steven Lin, MD, PhD @StevenLin_MDPhD of @MDAndersonNews answers if this can be extended to the community on the randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer. ____________ It is uncertain if the dosimetric advantages of proton beam therapy (PBT) lead to better health results as opposed to intensity-modulated radiation therapy (IMRT). This randomized trial compared total toxicity burden (TTB) and progression-free survival (PFS) between these esophageal cancer modalities. This phase IIB trial randomly allocated PBT or IMRT patients (50.4 Gy), stratified for histology, resectability, chemotherapy for induction, and level. TTB and…

Company completes CLIA Validation of DetermaIOâ„¢, previously the Insight Genetics IM Score Test, establishing the test as a reliable and robust assay for identifying patients likely to respond tocheckpoint inhibitor therapy Data presented at the SITC conference in 2019 suggested that DetermaIOâ„¢ outperforms PD-L1 testingand Tumor Mutational Burden (TMB) in predicting both responders and non-responders to checkpointinhibitors Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it had completed CLIA Validation for DetermaIOâ„¢, previously the Insight Genetics IM Score Test. The company…

Steven Lin, MD, PhD @StevenLin_MDPhD of @MDAndersonNews discusses the randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer. ____________ It is uncertain if the dosimetric advantages of proton beam therapy (PBT) lead to better health results as opposed to intensity-modulated radiation therapy (IMRT). This randomized trial compared total toxicity burden (TTB) and progression-free survival (PFS) between these esophageal cancer modalities. This phase IIB trial randomly allocated PBT or IMRT patients (50.4 Gy), stratified for histology, resectability, chemotherapy for induction, and level. TTB and PFS were the prespecified coprimary endpoints. TTB, a composite…

Sandra Swain, MD @SandraSwainMD of Georgetown Lombardi @LombardiCancer discusses the effects of cardiac toxicities in the phase 3 CLEOPATRA study in HER2 metastatic breast cancer. ____________ CLEOPATRA was a phase 3 trial comparing the efficacy and protection of pertuzumab, trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer with placebo, trastuzumab and docetaxel. In the primary study and subsequent studies, progression-free and overall survival in the pertuzumab group were substantially improved over placebo group. Here, we report CLEOPATRA’s final-of-study review. Read here: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30863-0/fulltext

Sandra Swain, MD @SandraSwainMD of Georgetown Lombardi @LombardiCancer answers common questions in the phase 3 CLEOPATRA study in HER2 metastatic breast cancer. Does this data reflect our everyday practice? ____________ CLEOPATRA was a phase 3 trial comparing the efficacy and protection of pertuzumab, trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer with placebo, trastuzumab and docetaxel. In the primary study and subsequent studies, progression-free and overall survival in the pertuzumab group were substantially improved over placebo group. Here, we report CLEOPATRA’s final-of-study review. Read here: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30863-0/fulltext

Sandra Swain, MD @SandraSwainMD of Georgetown Lombardi @LombardiCancer discusses findings in the phase 3 CLEOPATRA study in HER2 metastatic breast cancer. ______________ CLEOPATRA was a phase 3 trial comparing the efficacy and protection of pertuzumab, trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer with placebo, trastuzumab and docetaxel. In the primary study and subsequent studies, progression-free and overall survival in the pertuzumab group were substantially improved over placebo group. Here, we report CLEOPATRA’s final-of-study review. Read here: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30863-0/fulltext

Experience with COVID-19 in Wuhan, China shows up to half of patients present with a digestive symptom as chief complaint Digestive symptoms are common in COVID-19, occurring as the chief complaint in nearly half of patients presenting to hospital according to a new descriptive, cross-sectional multicenter study from China by investigators from the Wuhan Medical Treatment Expert Group for COVID-19 published today in The American Journal of Gastroenterology, the official publication of the American College of Gastroenterology. Most patients with COVID-19 present with typical respiratory symptoms and signs. However, early experience with the outbreak in Wuhan, China revealed that many patients…

Experts from Seattle Cancer Care Alliance share lessons learned from early experiences treating people with cancer during COVID-19 outbreak via free online article in JNCCN—Journal of the National Comprehensive Cancer Network Experts from the Seattle Cancer Care Alliance (SCCA)—a Member Institution of the National Comprehensive Cancer Network® (NCCN®)—are sharing insights and advice on how to continue providing optimal cancer care during the novel coronavirus (COVID-19) pandemic. SCCA includes the Fred Hutchinson Cancer Research Center and the University of Washington, which are located in the epicenter of the COVID-19 outbreak in the United States. The peer-reviewed article sharing best practices is available for free online-ahead-of-print via open access…

Cherie-Ann O. Nathan, MD of LSU Health Shreveport @LSUHS @LSUHealthNO answers if this will affect clinicians and treatment for progression-free survival for breast and kidney cancer may extend survival for head and neck cancer patients. ______________ A targeted therapy medication used for breast and kidney cancers can also improve progression-free survival after routine care for patients with advanced head and neck cancer who are at high risk of recurrence. Patients involved in this phase II randomized study who received the everolimus mTOR inhibitor were more likely to be cancer-free one year after treatment than those receiving a placebo drug, and…

Cherie-Ann O. Nathan, MD of LSU Health Shreveport @LSUHS @LSUHealthNO answers what type of TP53 mutations benefited from this for a drug used for breast and kidney cancer may extend survival for head and neck cancer patients. _______________ A targeted therapy medication used for breast and kidney cancers can also improve progression-free survival after routine care for patients with advanced head and neck cancer who are at high risk of recurrence. Patients involved in this phase II randomized study who received the everolimus mTOR inhibitor were more likely to be cancer-free one year after treatment than those receiving a placebo…

Cherie-Ann O. Nathan, MD of LSU Health Shreveport @LSUHS @LSUHealthNO answers questions on immunotherapy for a drug used for breast and kidney cancer may extend survival for head and neck cancer patients. _______________ A targeted therapy medication used for breast and kidney cancers can also improve progression-free survival after routine care for patients with advanced head and neck cancer who are at high risk of recurrence. Patients involved in this phase II randomized study who received the everolimus mTOR inhibitor were more likely to be cancer-free one year after treatment than those receiving a placebo drug, and the advantage continued…

Cherie-Ann O. Nathan, MD of LSU Health Shreveport @LSUHS @LSUHealthNO discusses a drug used for breast and kidney cancer may extend survival for head and neck cancer patients.  _______________ A targeted therapy medication used for breast and kidney cancers can also improve progression-free survival after routine care for patients with advanced head and neck cancer who are at high risk of recurrence. Patients involved in this phase II randomized study who received the everolimus mTOR inhibitor were more likely to be cancer-free one year after treatment than those receiving a placebo drug, and the advantage continued for those with mutations…

 VENCLYXTO® plus obinutuzumab is the first chemotherapy-free, fixed-duration combination regimen approved by the European Commission (EC) for patients with previously untreated chronic lymphocytic leukemia (CLL)   – Approval is based on data from the Phase 3 CLL14 trial, which showed that patients treated with obinutuzumab plus one year of treatment with VENCLYXTO had superior progression-free survival (PFS) and higher rates of undetectable minimal residual disease compared to patients receiving a standard of care chemoimmunotherapy regimen of obinutuzumab and chlorambucil[1],[5]   NORTH CHICAGO, Ill., March 12, 2020 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that the European Commission (EC)…

Allison King, MD of Washington University School of Medicine @WUSTLmed answers the gender disparities in hematology research: how this will affect clinicians and treatment. ______________ Hematologists who complete a mentored training program report higher academic performance rates than those who do not; however, a study published today in Blood Advances indicates a small difference between male and female hematologists in the success rate. The report, which explored the effect of caregiving obligations on academic performance, found that men had on average one more first- or senior-authored publication than women, and nearly twice as many total publications. Interestingly, the study found that self-identification…

Allison King, MD of Washington University School of Medicine @WUSTLmed discusses the results on gender disparities in hematology research success. ______________ Hematologists who complete a mentored training program report higher academic performance rates than those who do not; however, a study published today in Blood Advances indicates a small difference between male and female hematologists in the success rate. The report, which explored the effect of caregiving obligations on academic performance, found that men had on average one more first- or senior-authored publication than women, and nearly twice as many total publications. Interestingly, the study found that self-identification as a carer was…

Allison King, MD of Washington University School of Medicine @WUSTLmed discusses the study on gender disparities in hematology research success. ______________ Hematologists who complete a mentored training program report higher academic performance rates than those who do not; however, a study published today in Blood Advances indicates a small difference between male and female hematologists in the success rate. The report, which explored the effect of caregiving obligations on academic performance, found that men had on average one more first- or senior-authored publication than women, and nearly twice as many total publications. Interestingly, the study found that self-identification as a carer…

Tom Davis, MD @ThomasADavisMD of @GenoceaBio answers the advancing part B of GEN-009 phase 1/2a trial with first patient dosed with initial clinical results: a possible impact on broader therapy. Continuing challenges in the area of cancer immunotherapy and vaccination, particularly the current unmet need to produce treatments that translate into meaningful results for patients. The significance on the clinical progress Genocea has made to persevere and resolve the almost insurmountable roadblocks faced by other companies while making unparalleled progress.   

Tom Davis, MD @ThomasADavisMD of @GenoceaBio answers the advancing part B of GEN-009 phase 1/2a trial with first patient dosed with initial clinical results: what is the mechanism and how does it work?  Continuing challenges in the area of cancer immunotherapy and vaccination, particularly the current unmet need to produce treatments that translate into meaningful results for patients. The significance on the clinical progress Genocea has made to persevere and resolve the almost insurmountable roadblocks faced by other companies while making unparalleled progress.   

Tom Davis, MD @ThomasADavisMD of @GenoceaBio discusses the advancing part B of GEN-009 phase 1/2a trial with first patient dosed with initial clinical results in Q2/Q3 2020. Continuing challenges in the area of cancer immunotherapy and vaccination, particularly the current unmet need to produce treatments that translate into meaningful results for patients. The significance on the clinical progress Genocea has made to persevere and resolve the almost insurmountable roadblocks faced by other companies while making unparalleled progress.   

Thomas Moran, PhD of @MountSinaiNYC @IcahnMountSinai discusses advance novel biotherapies for treating cancer and coronavirus COVID-19 and new projects that are either oncologically oriented or immune regulatory. #cancer #covid19 #coronavirus #immune #cancer #biotherapies #treatment #covid19 #coronavirus _____________ Mount Sinai Health System and Harbour BioMed (HBM) have entered into a multi-year partnership to create new, fully human antibodies to treat and prevent various diseases including oncology and immunology. The collaboration will also use the H2L2 Harbor Mice ® platform to produce monoclonal antibodies against the coronavirus SARS CoV 2 – COVID-19 (commonly known as COVID-19).These fully human monoclonal antibodies may be…

Thomas Moran, PhD of @MountSinaiNYC @IcahnMountSinai discusses advance novel biotherapies for treating cancer and coronavirus COVID-19. #cancer #biotherapies #treatment #covid19 #coronavirus __________ Mount Sinai Health System and Harbour BioMed (HBM) have entered into a multi-year partnership to create new, fully human antibodies to treat and prevent various diseases including oncology and immunology. The collaboration will also use the H2L2 Harbor Mice ® platform to produce monoclonal antibodies against the coronavirus SARS CoV 2 – COVID-19 (commonly known as COVID-19).These fully human monoclonal antibodies may be used therapeutically for people exposed to the virus, or prophylactically for people at high risk…

Neeraj Agarwal, MD @neerajaiims of @huntsmancancer discusses post-hoc review of data from the TITAN Phase 3 trial on time to second deterioration (PFS2) or death at any point for patients undergoing hormone versus taxane therapy following initial ERLEADA ® treatment efficacy and safety results in high- versus low-risk patients with mCSPC affecting clinicians and treatment. #prostate #cancer #metastaticprostatecancer #TITAN #TITANstudy #PFS2 #HuntsmanCancer

Neeraj Agarwal, MD @neerajaiims of @huntsmancancer discusses post-hoc review of data from the TITAN Phase 3 trial on time to second deterioration (PFS2) or death at any point for patients undergoing hormone versus taxane therapy following initial ERLEADA ® treatment efficacy and safety results in high- versus low-risk patients with mCSPC: how did the patients do? #prostate #cancer #metastaticprostatecancer #TITAN #TITANstudy #PFS2 #HuntsmanCancer

JNJ-6372, a dual-targeting EGFR-MET bispecific antibody, is being investigated for adults with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion mutations The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-61186372 (JNJ-6372) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. JNJ-6372 is an EGFR-mesenchymal epithelial transition factor (MET) bispecific antibody that targets activating and resistant EGFR and MET mutations and amplifications.[i] Currently, there are…

Neeraj Agarwal, MD @neerajaiims of @huntsmancancer discusses post-hoc review of data from the TITAN Phase 3 trial on time to second deterioration (PFS2) or death at any point for patients undergoing hormone versus taxane therapy following initial ERLEADA ® treatment efficacy and safety results in high- versus low-risk patients with mCSPC.  #prostate #cancer #metastaticprostatecancer #TITAN #TITANstudy #PFS2 #HuntsmanCancer

Saghi Ghaffari, MD, PhD of @MountSinaiNYC @sinaistemcell answers a way to enhance the potency of blood-forming stem cells: how does this affect clinicians today? _____________ Researchers at Mount Sinai have found a way to boost the potency of blood-forming stem cells, potentially opening the door to a new approach to bone marrow transplantation, according to a report published in Cell Stem Cell on February 27. Blood-forming stem cells, known as hematopoietic stem cells (HSCs), are rare and seriously restrict bone marrow transplantation, which can treat many blood diseases and solid tumours. The Mount Sinai team reports that modulation of metabolic…

Saghi Ghaffari, MD, PhD of @MountSinaiNYC @sinaistemcell answers a way to enhance the potency of blood-forming stem cells, potentially opening a new approach for bone marrow transplant: what about human stem cells? _______________ Researchers at Mount Sinai have found a way to boost the potency of blood-forming stem cells, potentially opening the door to a new approach to bone marrow transplantation, according to a report published in Cell Stem Cell on February 27. Blood-forming stem cells, known as hematopoietic stem cells (HSCs), are rare and seriously restrict bone marrow transplantation, which can treat many blood diseases and solid tumours. The…

Saghi Ghaffari, MD, PhD of @MountSinaiNYC @sinaistemcell discusses a way to enhance the potency of blood-forming stem cells, potentially opening a new approach for bone marrow transplant. _______________ Researchers at Mount Sinai have found a way to boost the potency of blood-forming stem cells, potentially opening the door to a new approach to bone marrow transplantation, according to a report published in Cell Stem Cell on February 27. Blood-forming stem cells, known as hematopoietic stem cells (HSCs), are rare and seriously restrict bone marrow transplantation, which can treat many blood diseases and solid tumours. The Mount Sinai team reports that…

Mount Sinai researchers have discovered a way to enhance the potency of blood-forming stem cells, potentially opening the door to a new approach for bone marrow transplantation, according to a study being published on February 27 in Cell Stem Cell. The scarcity of blood-forming stem cells, known as hematopoietic stem cells (HSCs), severely limits bone marrow transplantation, which can cure many blood disorders and solid tumors. The Mount Sinai team reports that manipulation of metabolic activity around lysosomes, the storage and recycling centers within cells, can increase by more than 90-fold the potency of blood-forming stem cells in bone marrow transplantation.…

Collaboration combines Harbour BioMed’s proprietary H2L2 Harbour Mice® platform for fully human monoclonal antibody generation with Mount Sinai’s translational medical research expertise. NEW YORK, NY, CAMBRIDGE, MA, ROTTERDAM, NL, and SUZHOU, CN - Mount Sinai Health System and Harbour BioMed (HBM) have entered into a multi-year, multifaceted collaboration to develop novel, fully human antibodies for the treatment and prevention of various diseases including oncology and immunology. The collaboration will also utilize the H2L2 Harbour Mice® platform to generate monoclonal antibodies against the coronavirus SARS CoV 2 – COVID-19 (commonly known as COVID-19).These fully human monoclonal antibodies could be used therapeutically for people who…

The standard of care for small-cell lung cancer (SCLC) had been unchanged for over 20 years, with platinum-based chemotherapy being the treatment of choice for extensive-stage (ES) disease. However, in 2018, the approval of Bristol-Myers Squibb’s Opdivo (nivolumab) in the second-line setting marked the beginning of the immunotherapy era for ES-SCLC. Sakis Paliouras, Oncology and Hematology Analyst at GlobalData, comments: “The US Food and Drug Administration (FDA) approved Genentech’s Tecentriq (atezolizumab) in combination with chemotherapy as a first-line treatment for ES-SCLC based on a 30% reduction in risk of death observed in the Phase III IMpower133 trial. This approval established…

Neal Shore, MD of Carolina Urologic Research Center @AtlanticUrology explains the randomized phase II study of sipuleucel-T with or without radium-223: how this affects clinicians and treatment today. ____________ New data to be presented on the effect of Nubeqa® (darolutamide) on cerebral blood flow in men with non-metastatic castration-resistant prostate cancer (nmCRPC) Presentations feature data on Xofigo® (radium Ra 223 dichloride), including real-world analyses and investigational combination therapies in men with certain types of prostate cancer WHIPPANY, N.J.–(BUSINESS WIRE)– Bayer announced today data from the Company’s evolving oncology portfolio will be presented at the 2020 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers…

Neal Shore, MD of Carolina Urologic Research Center explains the randomized phase II study of sipuleucel-T with or without radium-223 in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC). Commonly asked questions: would this be a good way for patients with mildly symptomatic predominately with bone lesions to combine therapy? ____________ New data to be presented on the effect of Nubeqa® (darolutamide) on cerebral blood flow in men with non-metastatic castration-resistant prostate cancer (nmCRPC) Presentations feature data on Xofigo® (radium Ra 223 dichloride), including real-world analyses and investigational combination therapies in men with certain types of prostate cancer Abstracts: 326, TPS384, 130, 32,…

Neal Shore, MD of Carolina Urologic Research Center explains the randomized phase II study of sipuleucel-T with or without radium-223 in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC). ______________ New data to be presented on the effect of Nubeqa® (darolutamide) on cerebral blood flow in men with non-metastatic castration-resistant prostate cancer (nmCRPC) Presentations feature data on Xofigo® (radium Ra 223 dichloride), including real-world analyses and investigational combination therapies in men with certain types of prostate cancer Abstracts: 326, TPS384, 130, 32, 50, 56, 125, 89, 59, 136, 223, 236 WHIPPANY, N.J.–(BUSINESS WIRE)– Bayer announced today data from the Company’s evolving oncology portfolio…

Neal Shore, MD of Carolina Urologic Research Center explains CBF in regions relevant to cognitive function with ENZA to DARO and PBO in healthy volunteers:how developed is the MRI technology? ______________   New data to be presented on the effect of Nubeqa® (darolutamide) on cerebral blood flow in men with non-metastatic castration-resistant prostate cancer (nmCRPC) Presentations feature data on Xofigo® (radium Ra 223 dichloride), including real-world analyses and investigational combination therapies in men with certain types of prostate cancer Abstracts: 326, TPS384, 130, 32, 50, 56, 125, 89, 59, 136, 223, 236 WHIPPANY, N.J.–(BUSINESS WIRE)– Bayer announced today data from the Company’s evolving…

Neal Shore, MD of Carolina Urologic Research Center explains CBF in regions relevant to cognitive function with ENZA to DARO and PBO in healthy volunteers:how developed is the MRI technology? ______________ New data to be presented on the effect of Nubeqa® (darolutamide) on cerebral blood flow in men with non-metastatic castration-resistant prostate cancer (nmCRPC) Presentations feature data on Xofigo® (radium Ra 223 dichloride), including real-world analyses and investigational combination therapies in men with certain types of prostate cancer Abstracts: 326, TPS384, 130, 32, 50, 56, 125, 89, 59, 136, 223, 236 WHIPPANY, N.J.–(BUSINESS WIRE)– Bayer announced today data from the Company’s evolving oncology…

Neal Shore, MD of Carolina Urologic Research Center explains cerebral blood flow (CBF) in regions relevant to cognitive function with enzalutamide compared to darolutamide and placebo in healthy volunteers. ____________ New data to be presented on the effect of Nubeqa® (darolutamide) on cerebral blood flow in men with non-metastatic castration-resistant prostate cancer (nmCRPC) Presentations feature data on Xofigo® (radium Ra 223 dichloride), including real-world analyses and investigational combination therapies in men with certain types of prostate cancer Abstracts: 326, TPS384, 130, 32, 50, 56, 125, 89, 59, 136, 223, 236 WHIPPANY, N.J.–(BUSINESS WIRE)– Bayer announced today data from the Company’s evolving oncology portfolio…

– If Approved by the European Medicines Agency, ALUNBRIG Would Become an Important First-Line Treatment Option for ALK+ NSCLC Patients – – Positive Opinion is Based on Data from Phase 3 ALTA-1L Trial, in which ALUNBRIG Demonstrated Superiority in both Overall and Intracranial Efficacy Compared to Crizotinib –   Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of ALUNBRIG (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously not…

NCCN celebrates 25th anniversary year; shares updates from oncology experts on leading-edge cancer management practices during NCCN 2020 Annual Conference in Orlando. #NCCN2020 — Cancer care providers will gather in Orlando on March 20-22 for the National Comprehensive Cancer Network® (NCCN®) 2020 Annual Conference: Celebrating 25 Years of NCCN. The three-day, in-person conference features more than 30 educational sessions on state-of-the-art practices in cancer care. Leading experts from NCCN’s 28 Member Institutions will present on new and emerging therapies, keys to optimization and implementation of treatment, and best practices in delivering oncology care across the continuum. “Cancer care has evolved dramatically since NCCN was founded 25…

Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first patient in Japan has initiated treatment in the global Phase 3 AGENT study.   Isofol’s drug candidate arfolitixorin is being evaluated in the first line of treatment of metastatic colorectal cancer (mCRC). The study is currently being conducted in the USA, Canada, Europe, Australia and now also in Japan. Isofol plans to start the trial in up to 15 clinics in Japan, in addition to the 80 clinics that are already open.   “A high pace is kept in our patient enrollment which enables the study’s…

While radiation is successfully used to treat breast cancer by killing cancer cells, inflammation caused as a side-effect of radiation can have a contrary effect by promoting the survival of triple-negative breast cancer cells, according to research published online in the International Journal of Radiation Biology by Jennifer Sims-Mourtada, Ph.D., director of Translational Breast Cancer Research at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute. Accounting for 15-20% of all breast cancers, triple-negative breast cancer is faster growing than other types of breast cancers. Dr. Sims-Mourtada’s latest study, “Radiation induces an inflammatory response that results in STAT3-dependent changes in cellular plasticity…

Andrew Krivoshik, MD of @AstellasUS discusses the FDA breakthrough therapy for PADCEV in combination with pembrolizumab in first-line advanced bladder cancer. ____________ – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for PADCEVTM (enfortumab vedotin-ejfv) in combination with Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting.…

Andrew Krivoshik, MD of @AstellasUS discusses the FDA breakthrough therapy for PADCEV in combination with pembrolizumab in first-line advanced bladder cancer and commonly asked questions. ____________ – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for PADCEVTM (enfortumab vedotin-ejfv) in combination with Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy…

Andrew Krivoshik, MD of @AstellasUS discusses the FDA breakthrough therapy for PADCEV in combination with pembrolizumab in first-line advanced bladder cancer. ____________ – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for PADCEVTM (enfortumab vedotin-ejfv) in combination with Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting.…

Breakthrough Therapy Designation Based on Initial Results from Phase 1b/2 EV-103 Clinical Trial – – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for PADCEVTM (enfortumab vedotin-ejfv) in combination with Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting. The FDA’s Breakthrough Therapy process is designed to…

Arlene Siefker-Radtke, MD of @MDAndersonNews answers the phase 1b/2 NORSE study: the importance of mutation testing.

Arlene Siefker-Radtke, MD of @MDAndersonNews answers the phase 1b/2 NORSE study: how this affects clinicians, patients and treatment today.

Arlene Siefker-Radtke, MD of @MDAndersonNews answers the phase 1b/2 NORSE study: does FGFR targeted therapy work better than an immune checkpoint inhibitor?

Arlene Siefker-Radtke, MD of @MDAndersonNews discusses the phase 1b/2 NORSE study on the treatment of metastatic urothelial carcinoma in patients with select FGFR alterations.

Nima Sharifi, MD @nimasharifimd of @CleClinicMD @ClevelandClinic discusses fundamental mechanism for other clinical outcomes and phenotypes. ___________ In a new Cleveland Clinic-led study published in JAMA Oncology, researchers show that a testosterone-related genetic variant – HSD3B1(1245C) – is associated with more aggressive disease and shorter survival in men with metastatic prostate cancer. This study – the first clinical trial validation of the relationship between HSD3B1 status and clinical outcomes – suggests that genetic testing for HSD3B1(1245C) may help physicians identify patients most likely to benefit from additional and more aggressive treatment. Nima Sharifi, M.D., of Cleveland Clinic’s Lerner Research Institute, and colleagues retrospectively analyzed data from 475…

Nima Sharifi, MD @nimasharifimd of @CleClinicMD @ClevelandClinic discusses HSD3B1(1245C) – how this affects clinicians and treatment today. _________ In a new Cleveland Clinic-led study published in JAMA Oncology, researchers show that a testosterone-related genetic variant – HSD3B1(1245C) – is associated with more aggressive disease and shorter survival in men with metastatic prostate cancer. This study – the first clinical trial validation of the relationship between HSD3B1 status and clinical outcomes – suggests that genetic testing for HSD3B1(1245C) may help physicians identify patients most likely to benefit from additional and more aggressive treatment. Nima Sharifi, M.D., of Cleveland Clinic’s Lerner Research Institute, and colleagues retrospectively analyzed data from…

Nima Sharifi, MD @nimasharifimd of @CleClinicMD @ClevelandClinic answers common questions between genetic variant and poor outcomes in men with metastatic prostate cancer; what is the frequency of this fast form of the enzyme? ______________ In a new Cleveland Clinic-led study published in JAMA Oncology, researchers show that a testosterone-related genetic variant – HSD3B1(1245C) – is associated with more aggressive disease and shorter survival in men with metastatic prostate cancer. This study – the first clinical trial validation of the relationship between HSD3B1 status and clinical outcomes – suggests that genetic testing for HSD3B1(1245C) may help physicians identify patients most likely to benefit from additional and more…

Nima Sharifi, MD @nimasharifimd of @CleClinicMD @ClevelandClinic discusses a link between genetic variant and poor outcomes in men with metastatic prostate cancer. _____________ In a new Cleveland Clinic-led study published in JAMA Oncology, researchers show that a testosterone-related genetic variant – HSD3B1(1245C) – is associated with more aggressive disease and shorter survival in men with metastatic prostate cancer. This study – the first clinical trial validation of the relationship between HSD3B1 status and clinical outcomes – suggests that genetic testing for HSD3B1(1245C) may help physicians identify patients most likely to benefit from additional and more aggressive treatment. Nima Sharifi, M.D., of Cleveland Clinic’s Lerner Research Institute, and…

Caregiving responsibilities found to negatively affect academic productivity, primarily for men Hematologists who complete a mentored training program experience greater levels of academic success than those who do not; however, a study published today in Blood Advances suggests a slight discrepancy in success levels between male and female hematologists. The study, which examined the effect of caregiving responsibilities on academic success, identified that, on average, men had one more first- or senior-authored publication than women, and almost twice as many total publications. Surprisingly, the study found that self-identification as a caregiver was associated with decreased productivity for men but not women. The American Society…

Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine @YaleCancer explains how oral therapies will impact the treatment landscape in myeloid malignancies.

Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine @YaleCancer considers what we have learned from understanding real-world evidence (RWE) in older patients with acute myeloid malignancies.

Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine @YaleCancer elaborates on the role of venetoclax in treatment of myelodysplastic syndromes (MDS).

Jasmine Zain, MD, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, shares outcomes from the PRIMO study investigating duvelisib in peripheral T-cell lymphoma (PTCL).

Jasmine Zain, MD, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, tells us about some of the novel approaches in development for the treatment of peripheral T-cell lymphoma (PTCL).

Jasmine Zain, MD, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, discusses the most impressive studies in the treatment of peripheral T-cell lymphoma (PTCL) presented at ASH 2019.

Jasmine Zain, MD, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, considers how peripheral T-cell lymphoma (PCL) therapy has evolved in recent years.

Christopher Yasenchak, MD, Willamette Valley Cancer Institute and Research Center, Associate Chair, Hematology Research, US Oncology Research, discusses the most impressive clinical presentations from ASH 2019 in the treatment of Hodgkin’s lymphoma.

Christopher Yasenchak, MD, Willamette Valley Cancer Institute and Research Center, Associate Chair, Hematology Research, US Oncology Research, tells us about the patient profile most suited for zanubrutinib in relapsed/refractory mantle cell lymphoma (MCL).

Christopher Yasenchak, MD, Willamette Valley Cancer Institute and Research Center, Associate Chair, Hematology Research, US Oncology Research, shares the design and results of the Phase 2 study investigating first-line brentuximab vedotin plus nivolumab in older patients with Hodgkin’s lymphoma.

Michael Wang, MD, Professor, Department of Lymphoma and Myeloma @MDAndersonNews offers his opinion on zanubrutinib as compared to other second-generation BTK inhibitors in the management of lymphoma.

Michael Wang, MD, Professor, Department of Lymphoma and Myeloma @MDAndersonNews offers his impression of the pivotal clinical data that lead to the FDA approval of zanubrutinib.

Michael Wang, MD, Professor, Department of Lymphoma and Myeloma @MDAndersonNews speculates on therapies for front-line and relapsed mantle cell lymphoma.

Michael Wang, MD, Professor, Department of Lymphoma and Myeloma @MDAndersonNews elaborates on the ZUMA-2 trial investigating anti-CD19 CAR-T cell therapy in mantle cell lymphoma.

Peter M. Voorhees, MD @LevineCancer shares the current thinking regarding treatment algorithms in relapsed/refractory multiple myeloma.

Peter M. Voorhees, MD @LevineCancer explains how daratumumab is changing the way multiple myeloma (MM) patients are treated today.

Peter M. Voorhees, MD @LevineCancer summarizes the design and outcomes of the Phase 2 Griffin study in newly diagnosed multiple myeloma (MM) patients.

Chaitra Ujjani, MD, Associate Professor, @SeattleCCA University of Washington, Fred Hutchinson Cancer Research Center, tells us about the results of the Phase 3 ELEVATE TN study, investigating acalabrutinib combined with obinutuzumab or alone versus obinutuzumab plus chlorambucil in patients with treatment-naive chronic lymphocytic leukemia (CLL).

Chaitra Ujjani, MD, Associate Professor, @SeattleCCA University of Washington, Fred Hutchinson Cancer Research Center, considers the ideal patient profile for zanubrutinib in relapsed/refractory mantle cell lymphoma (RR-MCL).

Chaitra Ujjani, MD, Associate Professor, @SeattleCCA University of Washington, Fred Hutchinson Cancer Research Center, offers her impression of the Phase 2 CAPTIVATE study investigating the BTK inhibitor ibrutinib plus venetoclax in the first-line treatment of chronic lymphocytic leukemia (CLL).

Chaitra Ujjani, MD, Associate Professor, @SeattleCCA University of Washington, Fred Hutchinson Cancer Research Center, offers opinion on how physicians should be thinking about the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL).

Chaitra Ujjani, MD, Associate Professor, @SeattleCCA University of Washington, Fred Hutchinson Cancer Research Center, tells us about Veneto-STOP study presented at ASH 2019.

Constantine Tam, MBBS, MD, Consultant Hematologist, Peter MacCallum Cancer Center, Melbourne, Australia, regarding the ideal patient profile in relapsed or refractory mantle cell lymphoma (MCL) for treatment with zanubrutinib.

Constantine Tam, MBBS, MD, Consultant Hematologist, Peter MacCallum Cancer Center, Melbourne, Australia, offers his impression of the pivotal clinical data that lead to the recent FDA approval of zanubrutinib.

Max Topp, MD, Professor and Head of Hematology, University Hospital of Wuerzburg Germany, on the development of a new risk management plan to potentially reduce the toxicity of CAR-T cell therapy.

Max Topp, MD, Professor and Head of Hematology, University Hospital of Wuerzburg Germany, shares the long-term results of the ZUMA-1 trial presented at ASH 2019.

– ALUNBRIG has Potential to Expand its Indication in ALK+ Metastatic Non-Small Cell Lung Cancer – – Prescription Drug User Fee Act (PDUFA) Target Action Date Set for June 23, 2020 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for the company’s supplemental New Drug Application (sNDA) to expand the use of ALUNBRIG (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. ALUNBRIG is a next-generation tyrosine kinase inhibitor (TKI) that was designed to target…

 Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced its plan to initiate a Phase 1/2 study evaluating a triple combination of Compugen’s COM701, an investigational anti-PVRIG antibody, in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo® (nivolumab) and BMS-986207, Bristol-Myers Squibb’s investigational anti-TIGIT antibody. The triple combination study is designed to evaluate the blockade of the three immune checkpoint pathways – PVRIG, TIGIT and PD-1, and will accelerate the clinical evaluation of Compugen’s science-driven DNAM axis hypothesis in various advanced solid tumors. The study is expected to commence in the second half of 2020, following…

Constantine Tam, MBBS, MD, Consultant Hematologist, Peter MacCallum Cancer Center, offers his impression of the pivotal clinical data that lead to the recent FDA approval of zanubrutinib.

Constantine Tam, MBBS, MD, Consultant Hematologist, Peter MacCallum Cancer Center, offers his impressions of the Phase 2 CAPTIVATE study investigating the BTK inhibitor ibrutinib plus venetoclax in the 1st line treatment of chronic lymphocytic leukemia (CLL).

Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber shares thoughts on current treatment strategies for elderly acute myeloid leukemia (AML) patients.

Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber elaborates on prognostic factors and the relationship to outcomes in acute myeloid leukemia (AML) patients.

Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber offers his impression of the landscape for FLT3 inhibition in acute myeloid leukemia (AML).

Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber provides opinion on whether all acute myeloid leukemia (AML) patients should be tested for FLT3 mutations.

Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber describes the landscape of mutations and targeted therapy in acute myeloid leukemia (AML).

Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, @UCSFCancer discusses the prognostic factors in acute myeloid leukemia (AML) and how these factors relate to outcomes for patients.

Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, @UCSFCancer offers her overall impression on the changing FLT3 inhibition landscape in acute myeloid leukemia (AML).

Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, @UCSFCancer on whether there are emerging mutations in FLT3 mutated relapsed/refractory acute myeloid leukemia (AML) that respond to gilteritinib.

Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, @UCSFCancer on whether all acute myeloid leukemia (AML) patients should be tested for FLT3.

Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine @UCSFMedicine tells us about the outcomes of the Phase 3 ADMIRAL trial and why it is important to the management of acute myeloid leukemia.

Two-drug combination effective in lab studies against aggressive prostate tumors Research team identifies new approach to treating prostate cancer Metabolic targeting effective in lab study against aggressive prostate tumors Combining new, traditional approaches may prevent cancer recurrence A Roswell Park Comprehensive Cancer Center research team has identified a novel combination therapy that demonstrates a new approach to treating prostate cancer, reporting their findings in the journal Nature Communications. This new therapeutic strategy is the first to target metabolic processes uniquely important to prostate cancer — specifically, two enzymes in the connected polyamine catabolic pathway and the methionine salvage pathway.  Dr. Dominick Smiraglia and team…

Tanya Siddiqi, MD, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, elaborates on outcomes from the Phase 2 CAPTIVATE study investigating the BTK inhibitor ibrutinib plus venetoclax in the 1st line treatment of chronic lymphocytic lymphoma (CLL).

Tanya Siddiqi, MD, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, considers whether recent clinical data supports the use of CAR-T cell therapy in the management of lymphomas.

Tanya Siddiqi, MD, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, offers impressions of the Transcend-NHL data investigating the use of CAR-T cell therapy in chronic lymphocytic leukemia (CLL).

John Seymour, MBBS, PhD, Professor, Director of the Department of Hematology, Peter MacCallum Cancer Centre, Melbourne Australia, considers whether minimal residual disease (MRD) is a valid endpoint when measuring treatment efficacy in chronic lymphocytic leukemia (CLL).

John Seymour, MBBS, PhD, Professor, Director of the Department of Hematology, Peter MacCallum Cancer Centre, Melbourne Australia, tells us about the four-year update on the outcomes of the MURANO study, investigating venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

Robert Rifkin, MD, FACP, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, on whether medical oncologists are adopting therapeutic biosimilars in treatment algorithms.

Robert Rifkin, MD, FACP, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, offers opinion on the most promising studies in multiple myeloma (MM) presented at ASH 2019.

Robert Rifkin, MD, FACP, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, regarding the role of proteasome inhibitors in maintenance therapy for multiple myeloma patients.

Robert Rifkin, MD, FACP, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, explains the role of daratumumab as a maintenance therapy in the management of multiple myeloma (MM).

Joshua Richter, MD, Assistant Professor, Division of Hematology and Medical Oncology @TischCancer discusses the data investigating iberdomide presented at ASH 2019.

Adult cancer patients reported better physical and social function after undergoing CAR-T therapy Adult lymphoma patients whose disease was effectively treated with chimeric antigen receptor T-cell (CAR-T) therapy showed marked improvement on a variety of self-reported quality of life measures, according to a study published today in Blood Advances. The study offers evidence that CAR-T may not only extend cancer patients’ survival, but also improve their quality of life after treatment.Prior to the advent of CAR-T and other forms of cellular immunotherapy, patients with diffuse large B-cell lymphoma (DLBCL) had limited treatment options, and patients with advanced DLBCL had often already exhausted those…

Joshua Richter, MD, Assistant Professor, Division of Hematology and Medical Oncology @TischCancer provides opinion on the role of BCMA CAR-T cells in the management of multiple myeloma (MM).

Joshua Richter, MD, Assistant Professor, Division of Hematology and Medical Oncology @TischCancer considers the Phase 3 ICARIA-MM study investigating isatuximab in relapsed/refractory multiple myeloma patients.

Joshua Richter, MD, Assistant Professor, Division of Hematology and Medical Oncology @TischCancer tells us about the design and outcomes of the Phase 3 CANDOR study in relapsed/refractory multiple myeloma.

Leslie Popplewell, MD, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope considers whether there is sufficient evidence to use bridging therapy before CAR-T therapy.

Leslie Popplewell, MD, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope discusses clinical evidence supporting the use of CAR-T cell therapies in the treatment of aggressive B-cell lymphomas.

Leslie Popplewell, MD, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope discusses clinical evidence supporting the use of CAR-T cell therapies in the treatment of aggressive B-cell lymphomas.

Leslie Popplewell, MD, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope shares her thoughts on the role of CAR-T cell therapy in the treatment of aggressive B-cell lymphomas.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced the final data from its CTCL clinical trial of WP1220 for the treatment of cutaneous T-cell lymphoma (CTCL), which was published and presented by Dr. M. Sokolowska-Wojdylo in conjunction with the 4th Annual World Congress of Cutaneous Lymphomas in Barcelona, Spain on February 13, 2020.  The final results supported the safety of topical WP1220 and demonstrated a median improvement in the Composite Assessment of Index Lesion Severity (CAILS) score of 56% in treated (index) lesions for patients completing the…

Daniel Pollyea, MD, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, discusses prognostic factors in acute myeloid leukemia (AML) patients.

Daniel Pollyea, MD, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, discusses some of the novel agents, targeted therapies, and emerging strategies in the management of acute myelogenous leukemia (AML).

Daniel Pollyea, MD, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, elaborates on how the treatment of myelodysplastic syndromes is changing as a result of clinical data presented at ASH 2019.

Jae H. Park, MD, Associate, Leukemia Service, Department of Medicine, @sloan_kettering offers opinion on whether there is sufficient evidence to incorporate CAR-T cell therapies into acute leukemia treatment algorithms.

Jae H. Park, MD, Associate, Leukemia Service, Department of Medicine, @sloan_kettering shares clinical outcomes from the investigation of the vemurafenib combined with obinutuzumab in patients with hairy cell leukemia.

Gwen Nichols, MD, Chief Medical Officer-Physician, Scientific Research Portfolio, Patient Access Services, Policy and Advocacy Initiatives, Leukemia and Lymphoma Society, tells us about the collaboration between the Leukemia and Lymphoma Society and the American Society of Hematology.

Gwen Nichols, MD, Chief Medical Officer-Physician, Scientific Research Portfolio, Patient Access Services, Policy and Advocacy Initiatives, Leukemia and Lymphoma Society, elaborates on what the leukemia and lymphoma society is doing to help educate their membership on the novel agents and approaches.

Gwen Nichols, MD, Chief Medical Officer-Physician, Scientific Research Portfolio, Patient Access Services, Policy and Advocacy Initiatives, Leukemia and Lymphoma Society, offers opinion on the most exciting progress being made in the treatment of lymphoma, leukemia and multiple myeloma.

Gwen Nichols, MD, Chief Medical Officer-Physician, Scientific Research Portfolio, Patient Access Services, Policy and Advocacy Initiatives, Leukemia and Lymphoma Society, provides opinion on the most promising clinical presentations from ASH 2019.

Sattva Neelapu, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, tells us about the results of the ZUMA-1 study investigating axicabtagene ciloleucel in diffuse large b-cell lymphoma (DLBCL).

In a new Cleveland Clinic-led study published in JAMA Oncology, researchers show that a testosterone-related genetic variant – HSD3B1(1245C) – is associated with more aggressive disease and shorter survival in men with metastatic prostate cancer.   This study – the first clinical trial validation of the relationship between HSD3B1 status and clinical outcomes – suggests that genetic testing for HSD3B1(1245C) may help physicians identify patients most likely to benefit from additional and more aggressive treatment.   Nima Sharifi, M.D., of Cleveland Clinic’s Lerner Research Institute, and colleagues retrospectively analyzed data from 475 participants enrolled in a large, multi-center national clinical trial testing the efficacy of androgen deprivation…

Sattva Neelapu, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, considers whether off-the-shelf CAR-T cell therapy is becoming a reality.

Sattva Neelapu, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the role of off-the-shelf CAR natural killer (CAR NK) cell therapy in the treatment of B-cell malignancies.

Shyamala Navada, MD, MSCR, Associate Professor, Hematology and Medical Oncology, @MountSinaiNYC @IcahnMountSinai provides perspective on how oral therapies will impact the treatment landscape of myeloid malignancies.

Shyamala Navada, MD, MSCR, Associate Professor, Hematology and Medical Oncology, @MountSinaiNYC @IcahnMountSinai elaborates on the current approaches to treating elderly patients with myeloid malignancies.

Shyamala Navada, MD, MSCR, Associate Professor, Hematology and Medical Oncology, @MountSinaiNYC @IcahnMountSinai offers opinion on how the treatment of myelodysplastic syndromes (MDS) is changing, especially as a result of the clinical data presented at ASH 2019.

First time findings published in Nucleic Acids Research demonstrate the ability to differentiate exosomes from cancer cell subtypes from the same tumor type offering broad potential applications in biomarker discovery Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the publication of new data in Nucleic Acids Research, illustrating that use of the Company’s proprietary ADAPT Biotargeting Systemâ„¢ can lead to the identification of differences in protein expression patterns between exosomes from two related prostate cancer cell lines, vertebral cancer of the prostate (VCaP) and lymph node cancer of the prostate…

Nikhil Munshi, MD, Professor of Medicine, @HarvardHealth @harvardmed @DanaFarber Director of Basic and Correlative Science, discusses if there is an association between minimal residual disease (MRD) and long-term survival outcomes in multiple myeloma (MM)

Nikhil Munshi, MD, Professor of Medicine, @HarvardHealth @harvardmed @DanaFarber Director of Basic and Correlative Science, tells us about the outcomes of the CARTITUDE-1 study investigating JNJ-4528 directed against BCMA in relapsed/refractory multiple myeloma patients.

Pancreatic cancer has one of the worst survival rates among cancers. Patients can expect as low as a 9% chance to live for at least five years after being diagnosed. Going back in time to observe how cells with key gene mutations interact and become invasive would help researchers better understand how the cancer starts and identify it sooner. A pancreatic cancer “time machine” engineered by Purdue University researchers has revealed that the disease is even more unpredictable than previously thought: Cancer cells promote each other’s invasiveness when they grow together. The study, published in the journal Small, is just the beginning of…

James McCloskey, MD, Interim Chief, Division of Leukemia, John Theurer Cancer Center @HackensackUMC explains how the treatment of myelodysplastic syndromes (MDS) is changing as a result of clinical data presented at ASH 2019.

James McCloskey, MD, Interim Chief, Division of Leukemia, John Theurer Cancer Center @HackensackUMC explains how the treatment of myelodysplastic syndromes (MDS) is changing as a result of clinical data presented at ASH 2019.

James McCloskey, MD, Interim Chief, Division of Leukemia, John Theurer Cancer Center @HackensackUMC explains how the treatment of myelodysplastic syndromes (MDS) is changing as a result of clinical data presented at ASH 2019.

James McCloskey, MD, Interim Chief, Division of Leukemia, John Theurer Cancer Center, Part of Hackensack University Medical Center, shares his impression of the Phase 3 ASCERTAIN study investigating cedazuridine and decitabine versus decitabine in myelodysplastic syndromes (MDS).

Longeveron LLC, a leading developer of adult stem cell technologies for aging-related and life-threatening conditions, announced today that it has completed enrollment in its Phase 2b Aging Frailty trial.  This double-blinded, randomized, placebo-controlled study is designed to evaluate the safety and efficacy of LMSCs in patients with mild to moderate frailty.     This 150 subject multicenter study is sponsored in part by a Small Business Innovation Research (SBIR) Grant from the National Institute of Aging (NIA), as part of the Geroscience initiative focused on preventing and treating age-related conditions, functional decline, and disability. “We are extremely pleased to achieve this…

John Mascarenhas, MD Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology @IcahnMountSinai discusses whether molecular analysis is appropriate and helpful in determining treatment approaches for myeloproliferative neoplasms.

John Mascarenhas, MD Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology @IcahnMountSinai tells us about his approach to the individualized management of myeloproliferative neoplasms.

John Mascarenhas, MD Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology @IcahnMountSinai shares outcomes from the MANIFEST study investigating CPI-0610 as a monotherapy or add-on to ruxolitinib in patients with myelofibrosis.

Kylee Martens, MD Resident Physician, Internal Medicine @UWMedicine compares the effectiveness of rasburicase versus allopurinol in cancer patients with hyperuricemia.

Kylee Martens, MD Resident Physician, Internal Medicine @UWMedicine describes those patient types more suited for treatment with rasburicase versus allopurinol.

Kylee Martens, MD Resident Physician, Internal Medicine @UWMedicine discusses the advantages of rasburicase compared to allopurinol in managing tumor lysis syndrome (TLS) in patients with renal dysfunction.

Kylee Martens, MD Resident Physician, Internal Medicine @UWMedicine considers whether there are particular patient types more prone to tumor lysis syndrome (TLS).

Immunomedics has developed an antibody drug conjugate (ADC) called sacituzumab govitecan, which directly delivers chemotherapy SN-38 to triple negative breast cancer (TNBC) tumours, which highly express the glycoprotein Trop-2 and represents an unmet need within a highly treated cancer type. GlobalData’s pharmaceutical technology writer Allie Nawrat says: “The New Jersey-based firm has developed a novel ADC platform centred around its specialised hydrolysable linker, which delivers potent chemotherapy metabolites directly to cancer tumour sites and their microenvironments. “Immunomedics’ lead candidate, sacituzumab govitecan, is currently being developed for heavily treated TNBC patients. The company has received US Food and Drug Administration breakthrough…

Deepu Madduri, MD Assistant Professor, Medicine, Hematology and Medical Oncology, @MountSinaiNYC explains how JNJ-4528 differs from other CAR-T products.

Deepu Madduri, MD Assistant Professor, Medicine, Hematology and Medical Oncology, @MountSinaiNYC tells us about the outcomes of the CARTITUDE-1 study investigating JNJ-4528 directed against BCMA in relapsed refractory multiple myeloma.

Deepu Madduri, MD Assistant Professor, Medicine, Hematology and Medical Oncology, @MountSinaiNYC on how CAR-T cell therapy plays a role in the management of multiple myeloma.

Ryan Lynch, MD Assistant Professor of Medicine, Hematology/Oncology, University of Washington, @SeattleCCA offers opinion on how physicians should be thinking about the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL).

Ryan Lynch, MD Assistant Professor of Medicine, Hematology/Oncology, University of Washington, @SeattleCCA considers whether minimal residual disease (MRD) is a valid endpoint when measuring the efficacy of treatment in chronic lymphocytic lymphoma (CLL).

Ryan Lynch, MD Assistant Professor of Medicine, Hematology/Oncology, University of Washington, @SeattleCCA tells us about the four-year update on the outcomes of the MURANO study investigating venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic lymphoma.

Ryan Lynch, MD Assistant Professor of Medicine, Hematology/Oncology, University of Washington, @SeattleCCA considers the ideal patient profile for zanubrutinib in relapsed/refractory mantle cell lymphoma (RR-MCL).

Frederick Locke, MD Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, tells us about the data with CAR-T cell therapy outside of clinical trials.

Frederick Locke, MD Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, regarding the clinical evidence supporting CAR-T cell therapies in multiple myeloma.

Frederick Locke, MD Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, provides his impression of the Transcend-NHL study investigating the use of CAR-T cell therapy in diffuse large B-cell lymphoma (DLBCL).

Frederick Locke, MD Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, offers opinion regarding off-the-shelf CAR-T cell therapies.

Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, provides insight on the real-world evidence presented at ASH 2019 regarding CAR-T cell therapy in lymphoma.

Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, offers perspective on the role of umbralisib in the management of relapsed/refractory lymphoma.

Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphoma.

Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, discusses how physicians should be thinking about the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia.

Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, offers her perspective on the latest treatment trends in Burkitt lymphoma and other aggressive lymphomas.

Amrita Krishnan, MD Professor, Department of Hematology and Hematopoietic Cell Transplantation, @cityofhope tells us about the Phase 3 Dreamm-3 study, investigating belantamab versus pomalidomide and dexamethasone.

Amrita Krishnan, MD Professor, Department of Hematology and Hematopoietic Cell Transplantation, @cityofhope describes the results of the Phase 1 study investigating CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in patients with relapsed/refractory multiple myeloma.

Amrita Krishnan, MD Professor, Department of Hematology and Hematopoietic Cell Transplantation, @cityofhope tells us about the outcomes of the CARTITUDE-1 study investigating JNJ-4528 directed against BCMA in relapsed/refractory multiple myeloma.

Amrita Krishnan, MD Professor, Department of Hematology and Hematopoietic Cell Transplantation, @cityofhope elaborates on BCMA-directed strategies for multiple myeloma patients.

GRACE is very excited to bring to you more videos from our program, Supportive Care in Cancer Treatment.Arjun Gupta, MD is the host of this video series, Supportive Care in Cancer Treatment. In this video Dr. Gupta speaks with Christi M. Walsh, MSN, CRNP, with Johns Hopkins University in Baltimore, MD. Christi Walsh and Dr. Gupta discuss Pancreatic Enzyme Replacement Therapy, or PERT.To donate to CancerGRACE, visit https://cancergrace.org/donate.For more, please visit http://cancerGRACE.org/.To join the conversation, visit https://cancergrace.org/forum.

Arjun Gupta, MD is the host of this video series, Supportive Care in Cancer Treatment. In this video Dr. Gupta speaks with Shaalan Beg, MD, with UT Southwestern Medical Center in Dallas, TX . Dr. Beg and Dr. Gupta discuss Malignant Ascites, or fluid in the belly, in patients with cancer.To donate to CancerGRACE, visit https://cancergrace.org/donate.For more, please visit http://cancerGRACE.org/.To join the conversation, visit https://cancergrace.org/forum.

Source: https://www.spreaker.com/user/cancergrace/supportive-care-5-chemobrain-podcast We are very excited to bring to you this new program on supportive care in cancer treatment. In this video, our host Dr. Arjun Gupta speaks with his guest, Lysa Buonanno, who is a lung cancer patient and patient advocate. Lysa and Dr. Gupta discuss the often poorly understood subject of ‘chemobrain’, or attention, thinking or memory problems in patients with cancer. For more information on Chemobrain, please visit https://www.cancer.net/sites/cancer.net/files/asco_answers_chemobrain.pdf To join the conversation, visit https://cancergrace.org/forum. To find additional CancerGRACE resources, visit https://cancergrace.org. To donate to CancerGRACE, visit https://cancergrace.org/donate.

Source: https://www.spreaker.com/user/cancergrace/supportive-care-6-pert Arjun Gupta, MD is the host of this video series, Supportive Care in Cancer Treatment. In this video, Dr. Gupta speaks with Christi M. Walsh, MSN, CRNP, with Johns Hopkins University in Baltimore, MD. Christi Walsh and Dr. Gupta discuss Pancreatic Enzyme Replacement Therapy, or PERT.

Michael Jain, MD Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, @MoffittNews offers his opinion on off-the-shelf CAR-T cell therapy.

Michael Jain, MD Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, @MoffittNews tells us about the outcomes of the US CAR-T Cell Consortium study investigating bridging therapy prior to delivery of CAR-T cell therapy.

Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, @MoffittNews tells us about the outcomes of the US CAR-T Cell Consortium study investigating bridging therapy prior to delivery of CAR-T cell therapy.

Michael Jain, MD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, @MoffittNews discusses how population-based outcomes in B-cell lymphomas are changing.

Michael Jain, MD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, @MoffittNews offers perspective on the latest treatment trends for aggressive lymphomas.

Timothy Illidge, MD, PhD, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, @OfficialUoM shares the the primary and secondary endpoints of the ECHELON-2 study.

Timothy Illidge, MD, PhD, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, @OfficialUoM explains the purpose of targeting peripheral t-cell lymphoma (PTCL).

Timothy Illidge, MD, PhD, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, @OfficialUoM describes the ECHELON-2 data presented at ASH 2019.

Parameswaran Hari, MD Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, offers insight of the Phase 3 ICARIA-MM trial investigating isatuximab in relapsed/refractory multiple myeloma.

Parameswaran Hari, MD Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, tells us about the design and outcomes of the STORM and Mammoth studies, investigating refractory multiple myeloma (MM) patients treated with selinexor plus dexamethasone or conventional care.

Parameswaran Hari, MD Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, explains how novel combination treatment options and sequencing strategies are used to manage relapsed/refractory multiple myeloma.

Parameswaran Hari, MD Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, elaborates on the role of stem cell transplantation in the treatment of multiple myeloma.

Andre Goy, MD, Chairman, John Theurer Cancer Center, Part of @HackensackUMC considers whether off-the-shelf CAR-T cell therapies are becoming a reality.

Andre Goy, MD, Chairman, John Theurer Cancer Center, Part of @HackensackUMC offers impressions of the TRANSCEND-CLL-004 data investigating the use of CAR-T cell therapy in diffuse large B-cell lymphoma (DLBCL).

Andre Goy, MD, Chairman, John Theurer Cancer Center, Part of @HackensackUMC discusses the three-year survival analysis of the ZUMA-1 study investigating axicabtagene ciloleucel in diffuse large b-cell lymphoma (DLBCL) presented at ASH 2019.

Andre Goy, MD, Chairman, John Theurer Cancer Center, Part of @HackensackUMC tells us about the results of the ZUMA-2 study investigating anti-CD19 CAR-T cell therapy in mantle cell lymphoma (MCL) patients.

Bruce Feinberg, DO, Vice President, Clinical Affairs, Chief Medical Officer, @cardinalhealth explains how oncologists are using RWE today.

Bruce Feinberg, DO, Vice President, Clinical Affairs, Chief Medical Officer, @cardinalhealth provides examples of how real-world evidence (RWE) has impacted decision-making in oncology.

Bruce Feinberg, DO, Vice President, Clinical Affairs, Chief Medical Officer, @cardinalhealth defines real-world evidence (RWE) and explains how it can be used to aid physicians.

James Essell, MD, Medical Director, Blood Cancer Center, The Jewish Hospital-Mercy Health, discusses the future of off-the-shelf CAR-T cell therapy.

James Essell, MD, Medical Director, Blood Cancer Center, The Jewish Hospital-Mercy Health, discusses off the-shelf CAR natural killer (CAR NK) cell therapy in treating B-cell malignancies.

James Essell, MD, Medical Director, Blood Cancer Center, The Jewish Hospital-Mercy Health, offers his insight on the recent data investigating the bi-specific CAR-T cell therapy.

James Essell, MD, Medical Director, Blood Cancer Center, The Jewish Hospital-Mercy Health, discusses the integration of stem cell transplantation into the treatment of myeloma.

Courtney DiNardo, MD Associate Professor, Department of Leukemia, Division of Cancer Medicine, @MDAndersonNews provides insight on current treatment strategies for elderly acute myeloid leukemia (AML) patients.

Courtney DiNardo, MD Associate Professor, Department of Leukemia, Division of Cancer Medicine, @MDAndersonNews describes the targeted therapy landscape in acute myeloid leukemia (AML) today.

Courtney DiNardo, MD Associate Professor, Department of Leukemia, Division of Cancer Medicine, @MDAndersonNews explains how the treatment of acute myeloid leukemia (AML) patients has evolved over the years.

Courtney DiNardo, MD Associate Professor, Department of Leukemia, Division of Cancer Medicine, @MDAndersonNews considers whether intensive chemotherapy should be used upfront to treat newly diagnosed acute myeloid leukemia (AML) patients.

Catherine Diefenbach, MD, Director, Clinical Lymphoma Program, Perlmutter Cancer Center @nyulangone discusses how combination therapies are evolving to unmet needs in follicular lymphoma.

Catherine Diefenbach, MD, Director, Clinical Lymphoma Program, Perlmutter Cancer Center @nyulangone discusses the unmet needs of the Phase 1/2 study investigating obinutuzumab in relapsed/refractory follicular lymphoma.

Catherine Diefenbach, MD, Director, Clinical Lymphoma Program, Perlmutter Cancer Center @nyulangone tells us about the design and outcomes of the Phase 1/2 study investigating obinutuzumab in relapsed/refractory follicular lymphoma from ASH 2019.

Santosh Kesari, MD, PhD @DrKesari of @JohnWayneCI discusses a new clinical trial with the now approved drug, pemetrexed, for chordoma patients. Commonly asked questions are answered and he provides insight on standard treatment. _________ Brain Tumor Center affiliated with Providence Saint John’s Health Center The approved lung cancer drug pemetrexed is at the center of a new clinical trial at Providence Saint John’s Health Center’s Pacific Brain Tumor Center for patients diagnosed with chordoma, a rare, slow-growing cancer found in the bones at the base of the skull and the spine that is difficult to treat. Two chordoma patients who received the drug –…

Santosh Kesari, MD, PhD @DrKesari of @JohnWayneCI discusses a new clinical trial with the now approved drug, pemetrexed, for chordoma patients. __________ Brain Tumor Center affiliated with Providence Saint John’s Health Center The approved lung cancer drug pemetrexed is at the center of a new clinical trial at Providence Saint John’s Health Center’s Pacific Brain Tumor Center for patients diagnosed with chordoma, a rare, slow-growing cancer found in the bones at the base of the skull and the spine that is difficult to treat. Two chordoma patients who received the drug – approved by the FDA for lung cancer only – showed promising results…

Charis Eng, MD, Phd @CharisEngMDPhD of @ClevelandClinic @CCLRI explains some common questions regarding PTEN patients. _________ Cleveland Clinic researchers have identified for the first time an explanation of why patients with identical PTEN mutations often have vastly different clinical presentations. In a new study published in JAMA Network Open, a team of researchers led by Charis Eng, MD, PhD, of Cleveland Clinic Lerner Research Institute’s Genomic Medicine Institute, discovered that copy number variations (CNVs) may act as genomic modifiers that influence the risk of autism spectrum disorder (ASD) and/or developmental delay (DD) versus cancer risk in individuals with PTEN mutations.   Germline mutations of the tumor suppressor gene PTEN are…

Charis Eng, MD, Phd @CharisEngMDPhD of @ClevelandClinic @CCLRI clarifies genetic autism in PTEN patients. _______ Cleveland Clinic researchers have identified for the first time an explanation of why patients with identical PTEN mutations often have vastly different clinical presentations. In a new study published in JAMA Network Open, a team of researchers led by Charis Eng, MD, PhD, of Cleveland Clinic Lerner Research Institute’s Genomic Medicine Institute, discovered that copy number variations (CNVs) may act as genomic modifiers that influence the risk of autism spectrum disorder (ASD) and/or developmental delay (DD) versus cancer risk in individuals with PTEN mutations.   Germline mutations of the tumor suppressor gene PTEN are associated…

Angela Dispenzieri, MD Hematologist, Department of Hematology, @MayoClinic speculates on the clinical impact of the TOURMALINE-AL1 study.

Angela Dispenzieri, MD Hematologist, Department of Hematology, @MayoClinic shares the side effects of the TOURMALINE-AL1 study presented at ASH 2019.

Angela Dispenzieri, MD Hematologist, Department of Hematology, @MayoClinic shares the outcomes of the TOURMALINE-AL1 study presented at ASH 2019.

Angela Dispenzieri, MD Hematologist, Department of Hematology, @MayoClinic shares the design of the TOURMALINE-AL1 study presented at ASH 2019.